With an As­traZeneca can­cer drug in one hand, $37M in the oth­er, Shang­hai's Al­pha Bio zooms in­to a PhII study

One of the more promi­nent Chi­nese ven­ture firms in biotech has put some cash be­hind yet an­oth­er Chi­nese start-up look­ing to de­vel­op a Big Phar­ma drug for the boom­ing Asian mar­ket.

In what has fast be­come a rou­tine event, Qim­ing Ven­ture Part­ners led a $37 mil­lion Se­ries A tranche for Shang­hai-based Al­pha Bio­phar­ma. Al­pha Bio has plans to launch a glob­al, mul­ti-cen­ter Phase II clin­i­cal study of AZD3759, a TKI for EGFR mu­ta­tion-pos­i­tive cas­es of non-small cell lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER